This post is presented by our media partner Cannabis News Wire
View the original article here.
A recent publication in the “Medical Cannabis and Cannabinoids Journal,” authored by LECOM in collaboration with AYR Wellness (AYR), delves into the effects of medically approved cannabis on patients’ mental, social and physical well-being. The study showed that patients experienced notable enhancements across these domains, including increased energy levels, within the initial 30 days of treatment with medical cannabis.
This study is the partnership’s first publication; four further studies examining the medical benefits of cannabis are in the works.
The 90-day cohort study involved 103 adults (18 years of age and older) and was designed to evaluate the effects of medically prescribed cannabis on their psychological, social and physical well-being. Every 30 days, participants were required to complete electronic surveys tracking their overall quality of life and cannabis usage.
Furthermore, participants were required to document any negative effects they attributed to cannabis use, such as rapid heart rate, anxiety, dizziness, hallucinations or cognitive impairments. Additionally, participants had to disclose whether they consumed tobacco or alcohol products regularly during at least one-half of the study duration, including within the initial 30 days.
Analysis of the survey data revealed a substantial improvement in participants’ overall well-being and a significant decrease in pain levels between the 30- and 60-day intervals. Notably, individuals who used medical cannabis once daily exhibited the most significant enhancement in general health compared to those who consumed it more frequently, although this finding requires further validation due to the limited sample size of once-daily consumers (n=8).
Participants also reported reductions in emotional constraints, pain and fatigue. Those who consumed alcohol within the initial 30 days reported using medical cannabis less frequently and felt less emotional and energetic compared to nondrinkers. However, the frequency and quantity of alcohol consumption did not appear to influence these outcomes.
Individuals treating opioid addiction and PTSD with medical cannabis tended to use higher THC concentrations, whereas those managing anxiety and chronic pain opted for lower concentrations. Dry mouth, cough and increased appetite were the most commonly reported adverse effects, with no significant differences observed across frequency or modes of administration.
The authors noted that these findings contribute to destigmatizing medical cannabis use, highlighting its positive impact on patients’ lives over 90 days. They call for further research to comprehensively elucidate its medical efficacy and long-term effects.
This study goes on to confirm that patients accessing medical marijuana products from many of the licensed enterprises, such as Software Effective Solutions (d/b/a MedCana) (OTC: SFWJ) are actually deriving benefits from those products, in contrast to what detractors would want to believe.
NOTE TO INVESTORS: The latest news and updates relating to Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) are available in the company’s newsroom at https://cnw.fm/SFWJ
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is powered by IBN
This post was originally published by our media partner here.
